title: Congenital infections with Trypanosoma cruzi or Toxoplasma gondii are associated with decreased serum concentrations of interferon-γ and interleukin-18 but increased concentrations of interleukin-10.
abstract: Little is known about the immune responses of newborns with congenital Chagas disease (CCD) or congenital toxoplasmosis (CT) but they probably differ to those seen in adults with Chagas disease or toxoplasmosis, leading to differences in pathology. The concentrations of interleukin-18 (IL-18), interferon-γ (IFN-γ) and interleukin 10 (IL-10) in the sera of infants with CCD or CT were determined and compared with those in the sera of uninfected controls (born to mothers who were seropositive or seronegative for Trypanosoma cruzi). The infants with CCD or CT were found to have lower IL-18 and IFN-γ concentrations but higher IL-10 concentrations than the uninfected controls. The IL-18 and IFN-γ concentrations were also significantly lower in the infants with CCD than in those with CT. Although the infants with symptomatic CT had significantly higher serum concentrations of IL-18 than those with asymptomatic infection with Toxoplasma, the infants with symptomatic CCD had similar serum concentrations of IL-18 to the infants with asymptomatic Tr. cruzi infection. Taken together, these results indicate that IL-10 contributes to the suppression of pro-inflammatory immune responses and therefore, perhaps, to clinically overt CCD and CT.
authors.affiliation: Institut für Mikrobiologie und Hygiene, Charité Universitätsmedizin, Berlin, Germany.
authors.forename: J Patino
authors.initials: JP
authors.lastname: Mayer
authors.forename: M
authors.initials: M
authors.lastname: Biancardi
authors.forename: J
authors.initials: J
authors.lastname: Altcheh
authors.forename: H
authors.initials: H
authors.lastname: Freilij
authors.forename: T
authors.initials: T
authors.lastname: Weinke
authors.forename: O
authors.initials: O
authors.lastname: Liesenfeld
mesh_terms: D014355:Chagas Disease / Q000151:congenital* / Q000188:drug therapy / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007371:Interferon-gamma / Q000097:blood*; D016753:Interleukin-10 / Q000097:blood*; D020382:Interleukin-18 / Q000097:blood*; D008297:Male; D009547:Nifurtimox / Q000627:therapeutic use; D009593:Nitroimidazoles / Q000627:therapeutic use; D014125:Toxoplasmosis, Congenital / Q000188:drug therapy / Q000276:immunology*; D014344:Trypanocidal Agents / Q000627:therapeutic use
chemical_list: D020382:Interleukin-18; D009593:Nitroimidazoles; D014344:Trypanocidal Agents; D016753:Interleukin-10; D007371:Interferon-gamma; D009547:Nifurtimox; C009999:benzonidazole